文献速递介入泌尿生殖MRUSCT

前列腺动脉栓塞术后影像生物标志物现状与进展

Prostatic artery embolization and imaging-based biomarkers: current tools in monitoring treatment response and emerging strategies.
PubMed 文献 · Abdom Radiol (NY) · 2026-06-26

本文综述前列腺动脉栓塞术治疗良性前列腺增生相关下尿路症状后,用于评估治疗反应的影像生物标志物。重点讨论超声、MRI和CT在容积、功能、缺血及微结构评估中的作用。影像生物标志物可更客观地量化栓塞后变化,但需前瞻性验证。

要点

  • 前列腺分区容积参数比全腺容积更能预测症状改善。
  • 增强MRI缺血征象可直接反映栓塞后去血管化效果。
  • DWI/ADC可评估栓塞后组织重塑,b值选择影响早期梗死检出。

核心结论

  • 影像生物标志物为PAE疗效评估提供更客观框架,有助于标准化结局报告并早期识别治疗成败,但需更大规模PAE特异性队列的前瞻性验证。

研究设计与样本

  • 本文为综述,系统总结超声、MRI和CT在PAE疗效生物标志物评估中的应用并分析现有文献,未报告具体检索策略、纳入文献数量或样本量。

关键影像表现/征象

  • 容积生物标志物包括全前列腺容积、中央腺容积和分区容积指数,可量化腺体缩小程度。
  • 对比增强MRI显示的缺血征象可直接反映栓塞导致的去血管化。
  • DWI和ADC图可提供栓塞后组织重塑信息,b值选择影响早期梗死灶的检出。

诊断标准与关键数值

  • 分区容积参数与症状结局的相关性强于单纯全腺测量。
  • 功能性生物标志物如排尿后残余尿量可客观评估膀胱排空功能。

临床应用与阅片要点

  • 随访中可联合使用容积测量、残余尿量评估和增强MRI缺血评估,减少对IPSS等主观量表的依赖。
  • 报告PAE术后前列腺影像时,应描述中央腺与全腺容积变化,而不只报告全腺容积。
  • 使用DWI/ADC评估早期梗死时需注意b值选择对病灶检出的影响。

局限性

  • 超声弹性成像、影像组学和人工智能辅助分析仍需PAE特异性的前瞻性验证。
  • 影像生物标志物在临床广泛采用前仍需更大规模PAE特异性队列的前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Prostatic artery embolization (PAE) is a safe and effective minimally invasive treatment for lower urinary tract symptoms (LUTS) attributed to benign prostatic hyperplasia (BPH), including in patients with large prostates, who are poor surgical candidates or wish to avoid the morbidity of conventional surgery or transurethral interventions. As PAE becomes more widely adopted for BPH-related LUTS, objective measures of assessing treatment response are needed beyond symptom-based tools such as the International Prostate Symptom Score (IPSS) and Quality-of-Life (QoL) index. Imaging biomarkers complement these subjective endpoints by quantifying structural, functional, ischemic, and microstructural changes within the prostate before and after embolization. This review summarizes the principal imaging modalities used for biomarker assessment in PAE, with emphasis on ultrasound, magnetic resonance imaging (MRI), and computed tomography (CT) scans, and examines the current literature on imaging biomarkers of treatment response. Volumetric biomarkers, including whole prostate volume, central gland volume, and zonal volumetry index, provide quantitative assessment of gland reduction and may help predict clinical improvement, with zonal parameters showing stronger associations with symptomatic outcomes than whole-gland measurements alone. Functional biomarkers such as postvoid residual volume offer objective evaluation of bladder emptying alongside volumetric assessment, whereas ischemia-based biomarkers derived from contrast-enhanced MRI directly reflect embolization-induced devascularization. Diffusion-weighted imaging and apparent diffusion coefficient mapping provide additional information regarding post-embolization tissue remodeling, with b-value selection influencing early infarct detection. Emerging tools, including ultrasound elastography, radiomics, and artificial intelligence-assisted image analysis, may further refine patient selection, standardize response assessment, and improve predictive modeling, though prospective PAE-specific validation remains needed. Imaging biomarkers provide a more objective framework for evaluating PAE treatment response, with the potential to standardize outcome reporting, facilitate earlier identification of treatment success or failure, and guide biomarker-driven clinical decision-making. Prospective validation in larger PAE-specific cohorts remains essential before broader clinical adoption.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Wu, Lodhi, Tenney, et al. Prostatic artery embolization and imaging-based biomarkers: current tools in monitoring treatment response and emerging strategies. Abdom Radiol (NY). 2026. PMID: 42360341. doi:10.1007/s00261-026-05628-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。